China Grand to fund Sirtex buy with rights issue
China Grand Pharmaceutical and Healthcare Holdings has opted to pay for its acquisition of Australia-listed Sirtex Medical with a HK$2.9bn ($370m) rights issue.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: